Metropolis Healthcare records non-COVID revenues at Rs 288 crores in Q2FY23

Total B2C revenue grew by 25 per cent YoY in H1FY23 & 22 per cent in Q2FY23

Metropolis Healthcare has announced its unaudited consolidated financial results for the second quarter of financial year 2023.

Q2FY23 key highlights

• Wellness revenue increased by 40 per cent YoY to Rs 33 crores
• EBITDA margin (Before CSR & ESOP) stood at 27.6 per cent
• Specialised tests contributed 40 per cent to the Non-COVID revenue Q2FY23

Key highlights for core business#

• Total revenues grew by 12.4 per cent YoY
• Specialised tests revenues grew by 15 per cent YoY
• Wellness tests revenues grew by 36 per cent YoY
• Patient & tests volumes grew by 10 per cent YoY

 Q2FY23 financial highlights

• Rs 288 crores: Non-COVID revenue*
• Rs 83 crores: EBITDA (Before CSR & ESOP)
• Rs 41 crores: Profit after tax

Ameera Shah, Promoter and Managing Director, Metropolis Healthcare said, “I am extremely pleased to share that we have recorded highest ever quarterly revenue* with 16 per cent growth on year-on-year basis. With accelerated shift from the unorganised to the organised sector coupled with increased health awareness amongst customers and a trusted scientific image with medical fraternity, we expect the revenues growth to improve and margins to sustain at the pre-COVID levels. We have seen growth in our volumes & patient count and with increased investments in digital & marketing, manpower & customer experience initiatives, we are optimistic of sustaining the growth going forward. Our revenue contribution from wellness segment has increased to 12 per cent in Q2FY23 & has witnessed a healthy growth of 40 per cent on YoY basis; a testimony to our on-ground efforts and the acceptance of Metropolis Brand in the minds of consumers and medical fraternity.”

*Revenue excl. COVID PCR & COVID allied tests

#Excluding hi-tech and government contracts